Ibnsina Pharma (CAI:ISPH) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:ISPH Ibnsina Pharma CAI:ISPH
86 GF Score
Price E£11.50
GF Value E£10.54
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ibnsina Pharma Valuation Rank Related Terms

CAI:ISPH
86GF Score
Ibnsina Pharma CAI:ISPH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£11.50 is trading 9.1% above its estimated GF Value™ of E£10.54. GuruFocus considers Ibnsina Pharma to be Fairly Valued.

Key valuation signals for CAI:ISPH:

  • Valuation Rank:
  • GF Value™: E£10.54 vs. price of E£11.50 (9.1% above fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
86GF Score

Get the complete analysis for CAI:ISPH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£11.50
Price
E£10.54
GF Value